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Abstract. Controlled HumanMalaria Infection (CHMI) has become an increasingly important tool for the evaluation of
drugs and vaccines. Controlled Human Malaria Infection has been demonstrated to be a reproducible model; however,
there is some variability in time to onset of parasitemia between volunteers and studies. At our center, mosquitoes
infected with Plasmodium falciparum by membrane feeding have variable and high salivary gland sporozoite load (mean
78,415; range26,500–160,500). Todeterminewhether this load inﬂuencesparasitemia afterCHMI,weanalyzeddata from
13 studies. We found no correlation between the sporozoite load of a mosquito batch and time to parasitemia or parasite
density of ﬁrst-wave parasitemia. These ﬁndings support the use of infected mosquito bite as a reproducible means of
inducing P. falciparum infection and suggest that within this range, salivary gland sporozoite load does not inﬂuence the
stringency of a CHMI.
Controlled human malaria infection (CHMI) by the bites
of Plasmodium falciparum–infected, laboratory-reared
Anopheles mosquitoes have been used to study the in-
fection since the 1980s. In recent years, CHMI has become
highly standardized and is used to assess the efﬁcacy of
antimalarial drugs and vaccines before large-scale ﬁeld trials.
This has been possible in part because of the high repro-
ducibility of CHMI studies within and between centers.1
Nevertheless, there is variability in time to detectable
parasitemia between studies and between centers.2,3 As in
any biological system, there is signiﬁcant variability between
batches of infected mosquitoes used for CHMI, most notably in
the number of salivary gland sporozoites. Recently, CHMI
centers have increasingly started using intravenous in-
jection of cryopreserved P. falciparum sporozoites to initiate
infection,4,5 in part, because it is easier to standardize dosage.
However, using the natural route of infection via the mosquito
still has advantages over intravenous injection. Most impor-
tantly, it includes the immune response in the skin, which likely
plays a role in both vaccine-induced protection6 and the re-
sponse to primary infection.7
To test whether differences in salivary gland sporozoite
load between mosquito batches inﬂuenced the outcomes
of CHMI studies at our center, we collected data from all
past clinical trials since 2007 in which malaria-naive vol-
unteers were challenged with bites from ﬁve NF54 strain
P. falciparum–infected Anopheles mosquitoes, as de-
scribed previously.3 In these studies, mosquito batch
percent infectivity and sporozoite load were quantiﬁed
1 day before CHMI by dissection of salivary glands from a
sample of 10 mosquitoes per batch. Dissected salivary
glands were pooled and homogenized using a glass
grinder; sporozoites were quantiﬁed in a counting chamber
using a phase-contrast microscope. The mean salivary
gland sporozoite number per mosquito was calculated.
After the malaria infection, volunteers were followed up
once to three times daily from day 6 after infection until
3 days after the treatment of parasitemia. Quantitative
real-time polymerase chain reaction (qPCR) was per-
formed on blood samples either prospectively as the pri-
mary diagnostic test or retrospectively if thick blood
smears were used as the primary diagnostic test.8,9
We analyzed data from 13 CHMIs taking place between
2007 and 2016, involving 75 malaria-naive volunteers
(Table 1). Themean sporozoite load of themosquito batches
was variable, between 26,500 and 160,500 (mean 78,415;
95% conﬁdence interval: 59,627–97,204). We found no
correlation between the mean sporozoite load of the batch
used and the time to parasitemia detectable by qPCR
(Spearman r = 0.10), Figure 1A. Day 7 parasitemia can be
used as a reliable proxy measurement for liver parasite
burden: parasite density on day 7, after the challenge, cor-
relates stronglywith themean parasitemia of the ﬁrst wave of
parasites to emerge from the liver (N = 50; Spearman r= 0.90;
P < 0.0001), when antimalarial treatment is initiated after the
ﬁrst peak. There was no correlation between mosquito
sporozoite load and parasitemia on day 7 after CHMI
(Spearman r = 0.05), Figure 1B. Forty-nine volunteers (65%)
were exposed to exactly ﬁve mosquitoes, the rest required a
second exposure because either a mosquito was unfed or a
fed mosquito was uninfected. As unfed mosquitoes may still
have probed, possibly transmitting sporozoites, we per-
formed a second analysis adjusting the total infected mos-
quito exposure. Here, there was also no correlation with time
to parasitemia (Spearman r = 0.17) or day 7 parasitemia
(Spearman r = 0.06).
In CHMIs where the number of injected sporozoites is
precisely controlled, as in intravenous injection studies, in-
creasing the sporozoite number has an effect on prepatent
period; injection of 50 or 3,200 sporozoites resulted in a
prepatent of 13.3 and 11.2 days, respectively.4 However, this
analysis shows that between our CHMI trials, there is no
difference in infectivity to volunteers depending on salivary
gland sporozoite load of the mosquito batch used. In con-
trast, a recent study found that the probability of malaria
transmission to humans decreased when mosquitoes had
sporozoite loads of less than 1,000.10 However, only mos-
quitoes with 1–10, 11–100, 101–1,000, and > 1,000 sporo-
zoites were compared, a much lower load than the
mosquitoes used in our analysis. Taken together, these
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TABLE 1
Controlled human malaria infection studies used in this analysis
Year Trial registration number Number of volunteers
Sporozoite prevalence
(% mosquitoes infected)
Sporozoite intensity (mean
number of sporozoites per mosquito)
Study 1 2007 NCT00442377 5 80 31,500
Study 2 2008 NCT00509158 18 100 72,800
Study 3 2009 NCT00757887 5 96.5 88,000
Study 4 2010 NCT01002833 4 100 69,000
Study 5 2011 NCT01218893 5 100 79,500
Study 6 2012 NCT01422954 4 100 98,250
Study 7 2012 NCT01627951 5 100 101,250
Study 8 2012 NCT01728701 5 93.8 75,800
Study 9 2012 NCT01728701 4 100 98,000
Study 10 2015 NCT02080026 5 100 74,000
Study 11 2015 NCT02098590 2 90 26,500
Study 12 2015 NCT02098590 3 100 44,300
Study 13 2016 NCT02692963 10 100 160,500
Total 75
FIGURE 1. Correlation between Plasmodium falciparummosquito infection and infectivity to humans. The mean salivary gland sporozoite load
determined by the dissection of a sample of 10 mosquitoes compared with (A) the time to parasitemia detectable by PCR (> 100 parasites per
milliliter) and (B) the height of parasitemia on day 7 postinfection. Points and error bars show the median and interquartile range.
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observations suggest that above a certain threshold, more
sporozoites in the salivary glands no longer increase the
number of sporozoites transmitted.
In the past, ﬁndings on the association between the mos-
quito salivary gland load of P. falciparum and the number of
sporozoites injected by a salivating mosquito have been
contradictory, with some studies ﬁnding a correlation11 and
others not.12,13 In these studies, mosquitoes were typically
induced to salivate onto glass cover slips or into capillary
tubes. The number of sporozoites released during salivation
was shown to be between 1 and nearly 1,000 sporozoites per
mosquito, even when a much greater number was present in
the salivary glands.13,14 More recently, studies with live im-
aging of ﬂuorescent parasites have conﬁrmed that only a
small number of sporozoites are present in the mosquito
salivary ducts and that each mosquito injects tens to hun-
dreds of sporozoites during a feed.15,16 However, these
types of studies have always been conﬁned to rodentmalaria
models. Modeling of parasitemia after CHMI has calculated
that an infected mosquito transmits an average of 21 spo-
rozoites that successfully infect the liver,17 but studies di-
rectly linking the mosquito sporozoite load and liver
parasite burden of P. falciparum are lacking.
The current data support the idea that the number of spo-
rozoites injected by a feeding mosquito is independent of the
number in the salivary glands, at high infection intensities. It is
important to emphasize that all mosquito batches used in
these studies had salivary gland sporozoite loads far ex-
ceeding that found in the ﬁeld (usually less than 10,000).18
Other CHMI centers either have mosquito salivary gland
sporozoite loads that are much lower or in the same range as
the studies presented here.10,19,20 Irrespective of mosquito
sporozoite load,most of these studies have prepatent periods
similar to those at our center.9,19,20
A weakness of this analysis is that it used only pooledmean
mosquito batch sporozoite counts. In future studies, qPCR
can be applied to analyze individual mosquito sporozoite
loads in relation to volunteer prepatent periods. In such a
study, itwould alsobe interesting to generatemosquitoeswith
more variable sporozoite loads by titrating gametocyte con-
centration in their blood meal.
In conclusion, we demonstrate that the infectivity of mos-
quitoes tohumans inCHMIstudies at our center is independent
of the salivary gland sporozoite load of the mosquito batch
used. This ﬁnding supports theuse of infectedmosquito bite as
a reproducible means of inducing P. falciparum infection and
suggests that at high levels of infectivity, increased salivary
gland sporozoite load does not increase the stringency of a
mosquito challenge.
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